ArticleJournal of cheminformatics2026
ExPO: an exposure-conditioned neural operator for L1000 signature prediction.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Experimental profiling of drug-cell transcriptomic responses over dose and time is sparse and irregular, complicating discovery. We present ExPO, an exposure-conditioned neural operator that predicts full L1000 (978-gene) z-score signatures for a given compound-cell context as a continuous function of exposure. ExPO ifanstantiates a DeepONet, fusing ChemBERTa-2 molecular embeddings (with LoRA adaptation) and a trunk over sinusoidal Fourier features, so signatures can be evaluated at arbitrary dose-time pairs without regridding. Training is discovery-aligned, combining robust regression with a two-list listwise objective to optimize early-rank gene ordering, plus lightweight priors (Sobolev smoothness and an optional dose-monotonicity penalty) for pharmacologic plausibility. On a scaffold-held-out CMap/L1000 benchmark, ExPO improves over strong baselines in both accuracy and ranking (MAE 0.83 vs 0.89, Spearman 0.52 vs 0.48 vs DeepCE; NDCG@50↑/↓ 0.74/0.72 vs 0.71/0.69 for CIGER), tolerates withheld exposures (ΔMAE + 0.03 for interior interpolation; + 0.07 at edges, reduced by - 0.02 with the monotonicity prior), and transfers across cell lines (LCL-O MAE 0.90 vs 0.95; ρ 0.44 vs 0.40). Quantile heads with conformal calibration yield reliable uncertainty (test PICP 0.80/0.90), and filtering the least-confident 20% reduces MAE by ~ 18%. By modeling exposure as a field rather than discrete buckets, ExPO delivers accurate, rank-faithful, and calibrated signatures for in-silico exploration of dose-time surfaces. ExPO as a standalone predictor, along with its source code and benchmark dataset, is available at https://github.com/MLBC-lab/ExPO .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.